AAV-7A1

AAV-7A1
Name	AAV-7A1
Virus group	Dependoparvovirus
Family	Parvoviridae
Genus	Dependoparvovirus
Species	Adeno-associated virus serotype 7A1
Genome	Single-stranded DNA
Capsid	Non-enveloped, icosahedral
Discovery	21st century isolate (designation 7A1)
Host	Humans (cell lines), nonhuman primates, rodents (experimental)
Applications	Gene delivery, gene therapy research, CNS targeting

AAV-7A1

AAV-7A1 is a distinct adenovirus-associated parvoviral isolate used primarily as a vector platform in preclinical and translational research. It combines features of established adeno-associated virus serotypes with sequence variants that influence capsid antigenicity, tissue tropism, and transduction efficiency. Investigations into AAV-7A1 intersect with studies involving diverse strains and clinical programs led by institutions and companies exploring neurological, ocular, and muscular gene delivery.

Introduction

AAV-7A1 emerged within comparative surveys of adeno-associated virus isolates conducted by academic laboratories and biotechnology companies engaged with Massachusetts Institute of Technology, Stanford University, University of Pennsylvania, Imperial College London, and industry groups such as Novartis and Spark Therapeutics. Characterization parallels earlier work on serotypes like AAV1, AAV2, AAV5, AAV8, and AAV9 and follows frameworks established in regulatory interactions with agencies such as the Food and Drug Administration and European Medicines Agency. AAV-7A1 studies often reference landmark gene therapy trials, including programs at Royal Free Hospital and curated datasets from consortia like the Human Gene Therapy community.

Virology and Genome

As with other dependoparvoviruses characterized at Cold Spring Harbor Laboratory and Salk Institute, AAV-7A1 contains a linear single-stranded DNA genome approximately 4.7 kilobases in length, flanked by inverted terminal repeats first described in foundational work at University of Wisconsin–Madison and Johns Hopkins University. Its genome encodes rep and cap open reading frames comparable to those mapped in seminal studies at Harvard Medical School and University of California, San Francisco. Comparative genomics referencing sequences from National Institutes of Health repositories and analyses by groups at Broad Institute and European Bioinformatics Institute reveal variant residues within cap that distinguish AAV-7A1 from canonical serotypes cataloged by investigators at University College London.

Serotype Classification and Capsid Structure

Classification of AAV-7A1 follows serotyping conventions refined in series of structural studies at European Molecular Biology Laboratory, Max Planck Institute, and Argonne National Laboratory. Capsid architecture retains the icosahedral symmetry elucidated by cryo-electron microscopy teams at University of Oxford and Yale University, with VP1, VP2, and VP3 stoichiometry similar to that reported by groups at Cold Spring Harbor Laboratory. Structural variation localizes to surface-exposed loops implicated in antigenicity, with comparative mapping referencing datasets from California Institute of Technology and ETH Zurich. These surface residues affect neutralizing epitopes studied in collaborations including Emory University and Mayo Clinic.

Tropism, Receptor Usage, and Cellular Entry

Tropism studies from laboratories at Columbia University, University of Tokyo, and Peking University indicate AAV-7A1 preferentially transduces certain neuronal, hepatic, and muscular cell types in model systems, complementing work on tropism determinants by researchers at Karolinska Institute and University of Toronto. Candidate primary receptors and co-receptors implicated in AAV family entry—based on ligand screens performed at Cold Spring Harbor Laboratory and Rockefeller University—inform AAV-7A1 cellular uptake hypotheses, with endocytic pathways characterized alongside studies from University of Cambridge and University of Chicago. Intracellular trafficking and nuclear uncoating parallels experiments led by teams at National Cancer Institute and Duke University.

Production, Purification, and Quantification

Production workflows for AAV-7A1 adapt scalable platforms developed by industry leaders including Genentech, Pfizer, and Bayer and academic process engineering from Massachusetts General Hospital and Vanderbilt University. Upstream methods employ transient transfection of HEK293 lines originally described at Thomas Jefferson University or baculovirus/Sf9 systems refined by collaborators at Merck and University of Texas Southwestern Medical Center. Downstream purification leverages affinity chromatography media pioneered at GE Healthcare and density gradient protocols compared in studies from National Institute of Standards and Technology. Quantification strategies reference digital PCR standards from European Pharmacopoeia and analytical ultracentrifugation assays detailed by American Association of Pharmaceutical Scientists.

Clinical and Research Applications

AAV-7A1 has been evaluated in preclinical models relevant to neurological disorders studied at Mount Sinai Hospital and muscular dystrophies investigated by groups at Johns Hopkins University School of Medicine and University of Florida. Its performance is contextualized with clinical milestones achieved by gene therapies from UniQure, Bluebird Bio, and AveXis and regulatory precedents like approvals influenced by work at Children's Hospital of Philadelphia. Research applications include reporter gene delivery, CRISPR/Cas payload studies associated with labs at Broad Institute and University of California, Berkeley, and optogenetic tool deployment tied to investigators at Cold Spring Harbor Laboratory and MIT Media Lab.

Safety, Immunogenicity, and Regulatory Considerations

Safety profiles for AAV-7A1 draw on immunogenicity frameworks developed through trials led by National Institutes of Health and safety reviews by World Health Organization panels. Neutralizing antibody prevalence studies reference seroepidemiology datasets from Centers for Disease Control and Prevention and transplant immunology work at Cleveland Clinic. Regulatory considerations adopt guidance documents and pharmacovigilance practices shaped by Food and Drug Administration and European Medicines Agency submissions, with manufacturing quality standards informed by International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use dialogues and oversight from institutions like Paul-Ehrlich-Institut.

Category:Adeno-associated viruses